ReviewJournal of clinical medicine2023
Bidirectional Association between Lichen Planus and Hepatitis C-An Update Systematic Review and Meta-Analysis.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Evaluation of Comorbidities and Treatment Outcome in Various Subtypes of Lichen Planus: A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- Lichen planus autoimmune comorbidities: A retrospective case control study.Dermatology online journal · 2026Article
- Erosive Lichen Planus With Ocular Involvement: A Case Report.The American journal of case reports · 2025Article
- Assessment of Oral Hygiene Behavioral and Demographic Risk Factors for Extrahepatic Manifestations of Hepatitis C.Medical sciences (Basel, Switzerland) · 2025Article
- Impaired Gustation in Liver Diseases: A Comprehensive Narrative Literature Review.Acta stomatologica Croatica · 2025Review
- Lichen planus-the role of age and gender in clinical appearance and treatment : A narrative review.Wiener medizinische Wochenschrift (1946) · 2025Review
- Persistent annular dermatosis: Unraveling the cause of a 2-year rash.JAAD case reports · 2025Article
- Impact of Direct-Acting Antivirals on Extrahepatic Manifestations in Chronic Hepatitis C: A Narrative Review with a Hermeneutic Approach.Healthcare (Basel, Switzerland) · 2025Review
- Hydroxychloroquine is safe and efficacious in oral lichen planus: data from a large outpatient cohort.Archives of dermatological research · 2025Article
- Article
- Sequential Use of Apremilast, Total Glucosides of Paeony, and Periodontal Therapy in Refractory Plurimucosal Lichen Planus: A Case Report.Case reports in dentistry · 2025Article
- Lichen Planus Pigmentosus as a Cutaneous Extrahepatic Manifestation of Chronic Hepatitis C Virus Infection: A Case Report.International medical case reports journal · 2025Article
- Role of Vitamin D in Oral Lichen Planus: A Case Control Study.Nutrients · 2024Article
- Hepatitis C Virus (HCV) Infection: Pathogenesis, Oral Manifestations, and the Role of Direct-Acting Antiviral Therapy: A Narrative Review.Journal of clinical medicine · 2024Review
- Survey of Medical Referral by Japanese Dentists for Patients With Hepatitis B, Hepatitis C, and Lichen Planus.Cureus · 2024Article
- Crossroads between Skin and Endocrine Glands: The Interplay of Lichen Planus with Thyroid Anomalies.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen planus (LP) is a chronic, inflammatory mucocutaneous disorder associated with systemic diseases such as hepatitis C (HCV). The objective of this study is to evaluate the association between LP and HCV bidirectionally through a systematic review and meta-analysis. A comprehensive search of studies published was performed in the databases of PubMed, Embase, and Web of Science. Out of 18,491 articles, 192 studies were included. The global prevalence of HCV positive (HCV+) in LP patients registered from 143 studies was 9.42% [95% confidence interval (CI), 7.27-11.58%], and from these, 84 studies showed HCV+ 4-fold more frequent in LP than a control group (OR, 4.48; 95% CI, 3.48-5.77). The global prevalence of LP in patients HCV+ recorded from 49 studies was 7.05% (95% CI, 4.85-9.26%), and from these, 15 registered a 3-fold more LP in HCV (OR, 3.65; 95% CI, 2.14-6.24). HCV+ in LP patients showed great geographic variability (OR, 2.7 to 8.57), and the predominantly cutaneous location was higher (OR, 5.95) than the oral location (OR, 3.49). LP in HCV+ patients was more frequent in the Eastern Mediterranean (OR, 5.51; 95% CI, 1.40-15.57). There is a higher prevalence of HCV+ in LP and vice versa than in the control group, especially in certain geographical areas that should be taken into consideration when doing screening in countries with an upper prevalence of HCV among the general population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.